このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Humanwell Healthcare (Group)Ltd マネジメント

マネジメント基準チェック /24

Humanwell Healthcare (Group)Ltd'sの CEO はXiafei Dengで、 Jun2020年に任命され、の在任期間は 25.33年です。は、会社の株式の0.098%を直接所有しており、その価値はCN¥ 29.96M 。経営陣と取締役会の平均在任期間はそれぞれ4.2年と8.6年です。

主要情報

Xiafei Deng

最高経営責任者

CN¥7.2m

報酬総額

CEO給与比率	n/a
CEO在任期間	4yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4.2yrs
取締役会の平均在任期間	8.6yrs

経営陣の近況

Recent updates

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

May 22

CEO（最高経営責任者

Xiafei Deng (60 yo)

4yrs

在職期間

CN¥7,185,300

報酬

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Xiafei Deng	President & Director	4yrs	CN¥7.19m	0.098% CN¥ 28.9m
Yajun Wu	CFO & VP	20.3yrs	CN¥2.08m	0.059% CN¥ 17.6m
Qianlun Li	VP & Secretary	11.1yrs	CN¥1.97m	0.019% CN¥ 5.5m
Wentao Du	Vice President	20.7yrs	CN¥4.07m	0.056% CN¥ 16.5m
Lie Li	Vice President	4.2yrs	CN¥3.70m	0.032% CN¥ 9.4m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 8.3m
Qiang Yin	Vice President	4.2yrs	CN¥1.97m	0.028% CN¥ 8.3m
Qun Yu	Vice President	3.7yrs	CN¥3.69m	0.028% CN¥ 8.3m

4.2yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: 600079の経営陣は経験豊富であると考えられます ( 4.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Xiafei Deng	President & Director	25.3yrs	CN¥7.19m	0.098% CN¥ 28.9m
Min Qi	Supervisor	10.1yrs	データなし	データなし
Rui Zhou	Independent Director	3.1yrs	CN¥100.00k	データなし
Lin Qing Liu	Independent director	4.1yrs	CN¥100.00k	データなし
Xiao Dong Zhang	Director	27.4yrs	CN¥1.81m	0.029% CN¥ 8.5m
Xuehai Wang	Director	21.1yrs	CN¥618.50k	0.22% CN¥ 66.5m
Jie Li	Chairman of the Board	21.1yrs	CN¥5.67m	6.06% CN¥ 1.8b
Yue Xin Du	Chairman of the Supervisory Board	19.3yrs	CN¥66.00k	データなし
Hansheng Zhou	Director	7.2yrs	CN¥1.81m	データなし
Chenggang Zheng	Supervisor	4.1yrs	データなし	データなし
Kong Na	Representative Member of the Supervisory Board	4.1yrs	データなし	データなし
Xia Yuan	Employee Representative Member of the Supervisory Board	4.1yrs	データなし	データなし

8.6yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 600079の取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Humanwell Healthcare (Group)Ltd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24